Prognostic impact of histopathological features and serum inflammatory markers in patients with gastric cancer undergoing neoadjuvant therapy

doi:10.4240/wjgs.v17.i6.106517

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (170)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-3)

Sum=142

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=18

Jun 27, 2025 (publication date) through Jun 2, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Surg. Jun 27, 2025; 17(6): 106517
Published online Jun 27, 2025. doi: 10.4240/wjgs.v17.i6.106517

Open in New Tab Full Size Figure Download Figure

Figure 1 The survival rate of groups of patients. A: Disease-free survival graph in patients with albumin levels < 3.5 vs ≥ 3.5 g/dL; B: Overall survival graph in patients with albumin levels < 3.5 vs ≥ 3.5 g/dL; C: Disease-free survival graph in patients with and without adjuvant chemotherapy; D: Overall survival graph in patients with and without adjuvant chemotherapy.

Citation: Bulut N, Erdem GU, Kapagan T, Erol VB, Sahin T, Yakin M, Bayramgil A, Dülgar Ö. Prognostic impact of histopathological features and serum inflammatory markers in patients with gastric cancer undergoing neoadjuvant therapy. World J Gastrointest Surg 2025; 17(6): 106517
URL: https://www.wjgnet.com/1948-9366/full/v17/i6/106517.htm
DOI: https://dx.doi.org/10.4240/wjgs.v17.i6.106517